AMENDMENT NO. 1 TO ACTIVE INGREDIENT SUPPLY AGREEMENT
Exhibit
99.6
AMENDMENT
NO. 1
TO
This
Amendment No. 1 (this “Amendment”)
to the
Active Ingredient Supply Agreement is entered into and effective as of December
7, 2007 by and between Sirton Pharmaceuticals S.p.A. (“Sirton”)
and
Gentium S.p.A. (“Gentium”).
WHEREAS,
Gentium and Sirton entered into an Active Ingredient Supply Agreement effective
as of January 2, 2004 (the “Agreement”);
and
WHEREAS,
the parties wish to amend the Agreement.
NOW
THEREFORE, for good and valuable consideration, the receipt and sufficiency
of
which are hereby acknowledged, the parties hereto agree as follows:
1. Capitalized
terms used but not defined herein shall have the meanings set forth in the
Agreement.
2.
The
Agreement is hereby amended by removing Defibrotide for Injection and Oral
Defibrotide as active ingredients supplied by Gentium to Sirton.
3. Except
as
expressly amended hereby, the Agreement shall remain in full force and effect
in
accordance with its terms. This Amendment shall be deemed a part of, and
construed in accordance with, the Agreement. This Amendment may be executed
in
any number of counterparts, and with counterpart signature pages, all of which
together shall for all purposes constitute one Amendment.
[Signature
page to follow]
IN
WITNESS WHEREOF, this Amendment has been executed by a duly authorized officer
as of the date first above written.
|
Sirton
Pharmaceuticals S.p.A.
|
|||
|
By:
/s/
Xxxxx Xxxxxxx
|
By:
/s/
Xxxxxxxxx Xxxxxxxxx
|
||
|
Name:
Xxxxx Xxxxxxx
|
Name:
Xxxxxxxxx Xxxxxxxxx
|
||
|
Title:
Direttore Amministrativo e Finanziario
|
Title:
Vice-President, Finance
|
